Evidence map›Paper›PMID 17600311›Full record

ArticleAmerican journal of respiratory cell and molecular biology2007

EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells.

Ming Liu, Seok-Chul Yang, Sherven Sharma, Jie Luo, Xiaoyan Cui, Katherine A Peebles, Min Huang, Mitsuo Sato, Ruben D Ramirez, Jerry W Shay and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Amphiregulin and Fibrosis: Existing Evidence and Future Directions.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. [Advances of targeted therapy based on estrogen receptor signaling pathway in lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2011
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Tracheal Basal cells: a facultative progenitor cell pool.The American journal of pathology · 2010
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ming LiuLung Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California 90095, USA.
Seok-Chul Yang
Sherven Sharma
Jie Luo
Xiaoyan Cui
Katherine A Peebles
Min Huang
Mitsuo Sato
Ruben D Ramirez
Jerry W Shay
John D Minna
Steven M Dubinett
University of California, Los Angeles · USThe University of Texas Southwestern Medical Center · USVA Greater Los Angeles Healthcare System · USUSC Norris Comprehensive Cancer Center · USVeterans Health Administration · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
UCLA SPORE IN LUNG CANCERP50CA090388 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2001 to 2008
$13.0M
NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA70907NCI NIH HHS P50 CA90388
6 · The paper itself

Abstract

Cyclooxygenase-2 (COX-2) is a key enzyme in the production of prostaglandins and thromboxanes from free arachidonic acid. Increasing evidence suggests that COX-2 plays a role in tumorigenesis. A variety of stimuli induce COX-2 and it is overexpressed in many tumors, including non-small cell lung cancer (NSCLC). We studied the regulation of COX-2 expression in immortalized human bronchial epithelial cells (HBECs) by transforming growth factor-beta1 (TGF-beta1) and epidermal growth factor (EGF) because these two growth factors are present in both the pulmonary milieu of those at risk for lung cancer as well as in the tumor microenvironment. EGF significantly enhanced TGF-beta1-mediated induction of COX-2 and corresponding prostaglandin E2 (PGE2) production. TGF-beta1 and EGF induced COX-2 at the transcriptional and post-transcriptional levels. EGF receptor (EGFR) inhibition, neutralizing antibody against amphiregulin, or mitogen-activated protein kinase kinase (MEK) inhibition blocked TGF-beta1-mediated COX-2 induction. COX-2 induction by TGF-beta1 depended upon Smad3 signaling and required the activity of EGFR or its downstream mediators. Autocrine amphiregulin signaling maintains EGFR in a constitutively active state in HBECs, allowing for COX-2 induction by TGF-beta1. Thus, EGFR ligands, which are abundant in the pulmonary microenvironment of those at risk for lung cancer, potentiate and are required for COX-2 induction by TGF-beta1 in HBEC. These findings emphasize the central role of EGFR signaling in COX-2 induction by TGF-beta1 and suggest that inhibition of EGFR signaling should be investigated further for lung cancer prevention.

Indexed as

BronchiCell Line, TransformedCyclooxygenase 2DinoprostoneEnzyme InductionErbB ReceptorsHumansRespiratory MucosaSignal TransductionTransforming Growth Factor beta1Cyclooxygenase 2DinoprostoneErbB ReceptorsPTGS2 protein, humanTransforming Growth Factor beta1

Identifiers

PMID17600311
PMCPMC2048680
OpenAlexW1995260103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.